Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI Meeting Abstract
| Authors: | Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; O'Donnell, E.; Jackson, C. C.; Yeh, T.; Banerjee, A.; Zudaire, E.; Madduri, D.; Zhou, C.; Bubuteishvili-Pacaud, L.; Lin, Y.; Jagannath, S. |
| Abstract Title: | Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302066 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8028 |
| Notes: | Meeting Abstract: 8028 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work